

Editorial Note on Therapeutic Measures of Coronavirus

Maria Teresa Mascellino*

Department of Infectious Diseases, Sapienza University of Rome, Italy

***Corresponding author:** Maria Teresa Mascellino, Department of Infectious Diseases, Sapienza University of Rome, Italy; E-mail: mariateresa.mascellino@uniroma1.it

Received: June 16, 2021; **Accepted:** June 30, 2021; **Published:** July 0 , 2021

Copyright: © 2021 Mascellino MT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial Note

The continuous pandemic of COVID sickness 2019 (COVID-19) brought about by the extreme intense respiratory disorder COVID-19 (SARS-CoV-2) has conveyed a genuine general wellbeing intimidation worldwide with a great many individuals in danger in a developing number of nations. However there are no clinically endorsed antiviral medications and antibodies for COVID-19, endeavours are progressing for clinical preliminaries of a few known antiviral medications, their mix, just as improvement of immunizations in patients with affirmed COVID-19.

This survey centres on the furthest down the line ways to deal with diagnostics and treatment of COVID-19. We have summed up ongoing advancement on the customary therapeutics like antiviral medications, immunizations, against SARS-CoV-2 immunizer medicines, and healing plasma treatment which are presently under broad examination and clinical preliminaries for the treatment of COVID-19. The improvements of nanoparticle-based remedial and demonstrative methodologies have been likewise examined for COVID-19. We have surveyed late writing information on this subject and made a rundown of current turn of events and future viewpoints.

Recently arising infection sicknesses have become a significant general wellbeing danger all throughout the planet as of late. During the most recent twenty years, episodes of a few viral infections have been accounted for including the serious intense respiratory condition COVID (SARS-CoV) in 2002, H1N1 flu in 2009, the Middle East respiratory disorder COVID (MERS-CoV) in 2012, Ebola infection illness (EVD) in 2013, and Zika infection in 2015. The latest and continuous viral sickness brought about by mprial COVal